A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression

A Calderone1, N Abdelaziz, F Colombo

  • 1Université de Montréal, Departément de Physiologie et Biochimie, et l'Institut de Cardiologie de Montréal, Québec, Canada. calderon@icm.umontreal.ca

Insights

This study shows that inhibiting farnesyltransferase reduces cardiac myocyte hypertrophy stimulated by norepinephrine and endothelin-1, highlighting the role of ras signaling. It also suggests stimulus-specific, ras-independent pathways contribute to this response.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cell Signaling

Background:

  • Cardiac myocyte hypertrophy can be induced by oncogenic ras or calmodulin overexpression.
  • The involvement of ras and calmodulin in physiologically stimulated cardiac hypertrophy is not fully understood.

Purpose of the Study:

  • To investigate the roles of ras and calmodulin in norepinephrine- and endothelin-1-induced cardiac hypertrophy in neonatal rat myocytes.
  • To explore the signaling pathways, including ERK, involved in these hypertrophic responses.

Main Methods:

  • Pharmacological inhibition of farnesyltransferase (using BMS-191563) and calmodulin (using W7).
  • Measurement of 3H-leucine uptake and protein synthesis as indicators of hypertrophy.
  • Assessment of extracellular signal-regulated kinase (ERK) activity and natriuretic peptide mRNA expression (prepro-ANP, -BNP).

Main Results:

  • Farnesyltransferase inhibition significantly decreased norepinephrine- and endothelin-1-stimulated hypertrophy and ERK activity.
  • Calmodulin inhibition reduced norepinephrine-stimulated hypertrophy but not endothelin-1-stimulated hypertrophy.
  • Both inhibitors attenuated norepinephrine-induced natriuretic peptide mRNA expression, with BMS-191563 also affecting endothelin-1 responses to a lesser extent.

Conclusions:

  • The small GTP-binding protein ras plays a role in mediating cardiac hypertrophy in response to physiological stimuli like norepinephrine and endothelin-1.
  • Ras-independent signaling pathways are also involved in cardiac hypertrophy, with their recruitment being stimulus-specific.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...